Navigation Links
For Alzheimer's Disease, Surveyed Neurologists Identify a Therapy's Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
Date:4/29/2009

The Combination of Bapineuzumab and Donepezil Will Earn Decision Resources' Gold Standard Status for the Indication in 2012, According to a New Report from Decision Resources

WALTHAM, Mass., April 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists identify a therapy's effect on cognitive decline as the attribute that most influences their prescribing decisions in mild to moderate Alzheimer's disease. As potential disease-modifying drugs, interviewed thought leaders indicate that Elan/Wyeth's bapineuzumab, Eli Lilly's solanezumab and semagacestat, Medivation/Pfizer's Dimebon and Baxter Healthcare's Gammagard all have advantages in this attribute over donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in the market.

The new report entitled Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status also finds that a therapy that prevents cognitive decline for a longer duration than donepezil for the treatment of mild to moderate Alzheimer's disease would earn a 50 percent patient share in the United States and a 45 percent patient share in Europe, according to surveyed U.S. and European neurologists.

In 2008, Decision Resources' proprietary clinical gold standard for mild to moderate Alzheimer's disease was donepezil. Based on available data and expert opinion, the combination of bapineuzumab and donepezil will earn gold standard status for the indication in 2012, following the approval of bapineuzumab in 2012.

"The bapineuzumab/donepezil combination, as a potential disease-modifying drug, may have competitive advantages in efficacy outcomes, including effect on cognitive decline," said Decision Resources Director Andrea Witt, Ph.D. "Thought leaders perceive this regimen as having the greatest potential efficacy in Alzheimer's disease and preliminary clinical trial results suggest that monoclonal antibodies such as bapineuzumab may have a greater impact than other emerging agents on all efficacy measures."

About the Report

Alzheimer's Disease: New Therapies with the Potential for Disease Modification and Improved Efficacy Would Reach Blockbuster Status is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                     Decision Resources, Inc.
    Christopher Comfort                    Elizabeth Marshall
    781-296-2597                           781-296-2563
    ccomfort@dresources.com                emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Alzheimers Research Target May Be a Dead End
2. Renal function and heart disease, and more
3. Environmental stress probed in cardiovascular disease, diabetes
4. Study Links Coronary Disease, Colon Cancer
5. People with Schizophrenia More Likely to Die of Heart Disease, Reports the Harvard Mental Health Letter
6. To fight disease, animals, like plants, can tolerate parasites
7. Researchers Spot Link Between Heart Disease, Income
8. Children with sickle cell disease, silent strokes show some relief with blood transfusions
9. New studies on cancer and schizophrenia, depression and heart disease, trauma and autism
10. U.S. Deaths Down From Heart Disease, Stroke
11. Large Disparities in Kidney Testing Based on Disease, Gender and State, Quest Diagnostics Health Trends(TM) Report Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... UK (PRWEB) , ... May 06, 2016 , ... ... success in changing the way the pharmaceutical industry conducts clinical trials. This month Ibs ... most influential people in pharma, and he was honored as a Tech Disruptor by ...
(Date:5/6/2016)... ... ... variety of national pet product manufacturers, companies and brands will gather for one day only ... noon to 8 p.m. at New York City’s Roger Smith Hotel. The event is produced ... and safety pet products in today’s marketplace. , Petrend Event showcases the newest ...
(Date:5/6/2016)... , ... May 06, 2016 , ... Logically, spring weather, ... seasons, when the weather is too cold, dry or hot, water on the eye ... actually absorb moisture from the surrounding air. There’s only one problem, according to radio ...
(Date:5/6/2016)... ... 2016 , ... Canadian author Mark Black is a speaker, author, and life strategy ... the world … with the help of his publisher Strategic Book Group and its subsidiary ... a hospital bed waiting for a miracle: He needed a heart and double-lung transplant. From ...
(Date:5/6/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new article ... Bible about helping to stop cancer. Yisrayl says there are too many suffering and dying ... and science industries will pay close attention and take action. The Pastor says that the ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... TORONTO , May 5, 2016  Replikins Ltd. today reported initial promising results ... Photo - http://photos.prnewswire.com/prnh/20160505/364345 ... ... ... Replikins analyses of all Zika specimens recorded on Pubmed. The analysis identified the highest ...
(Date:5/5/2016)... 5, 2016  Diagnostic imaging has been on ... concerns that these tests cause health care costs to spike. ... as well as the adoption of new guidelines ... peripherals that help health care providers cut costs, while helping ... imaging is a renowned authorized reseller of the medical ...
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
Breaking Medicine Technology: